RT Generic
T1 Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin.
A1 Sorlozano-Puerto, Antonio
A1 Navarro-Mari, Jose Maria
A1 Gutierrez-Fernandez, Jose
K1 Animals
K1 Chickens
K1 Fosfomycin
K1 Campylobacter Infections
K1 Campylobacter jejuni
AB We read with interest the report by Aguilar-Company et al. (1) on two cases of recurrent enteritis due to Campylobacter coli successfully treated with oral fosfomycin-tromethamine. Campylobacter spp. are among the main microorganisms responsible for enteritis and are the principal cause of bacterial diarrhea in our setting, ahead of the genus Salmonella; they are responsible for 44.0% of cases, a percentage that has substantially increased over recent years (2). Although the disease is often mild and self-limiting, it is frequently observed in patients with immunologic alterations and there is growing resistance to macrolides and fluoroquinolones, increasing the risk of a lethal outcome (3).
PB American Society for Microbiology
YR 2017
FD 2017-01-24
LK http://hdl.handle.net/10668/10803
UL http://hdl.handle.net/10668/10803
LA en
NO Sorlózano-Puerto A, Navarro-Marí JM, Gutiérrez-Fernández J. Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e02317-16.
DS RISalud
RD May 11, 2025